Biocon Limited Fundamental Analysis
Biocon Limited (BIOCON.BO) shows weak financial fundamentals with a PE ratio of 149.10, profit margin of 2.28%, and ROE of 1.35%. The company generates $145.0B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 30.1/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze BIOCON.BO's fundamental strength across five key dimensions:
Efficiency Score
WeakBIOCON.BO struggles to generate sufficient returns from assets.
Valuation Score
ModerateBIOCON.BO shows balanced valuation metrics.
Growth Score
ModerateBIOCON.BO shows steady but slowing expansion.
Financial Health Score
ExcellentBIOCON.BO maintains a strong and stable balance sheet.
Profitability Score
WeakBIOCON.BO struggles to sustain strong margins.
Key Financial Metrics
Is BIOCON.BO Expensive or Cheap?
P/E Ratio
BIOCON.BO trades at 149.10 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, BIOCON.BO's PEG of -2.23 indicates potential undervaluation.
Price to Book
The market values Biocon Limited at 1.95 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 13.71 times EBITDA. This signals the market has high growth expectations.
How Well Does BIOCON.BO Make Money?
Net Profit Margin
For every $100 in sales, Biocon Limited keeps $2.28 as profit after all expenses.
Operating Margin
Core operations generate 16.91 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $1.35 in profit for every $100 of shareholder equity.
ROA
Biocon Limited generates $0.61 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Biocon Limited generates limited operating cash flow of $6.89B, signaling weaker underlying cash strength.
Free Cash Flow
Biocon Limited generates weak or negative free cash flow of $-493.35M, restricting financial flexibility.
FCF Per Share
Each share generates $-0.36 in free cash annually.
FCF Yield
BIOCON.BO converts -0.10% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
149.10
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-2.23
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.95
vs 25 benchmark
P/S Ratio
Price to sales ratio
3.37
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.45
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.22
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.01
vs 25 benchmark
ROA
Return on assets percentage
0.006
vs 25 benchmark
ROCE
Return on capital employed
0.06
vs 25 benchmark
How BIOCON.BO Stacks Against Its Sector Peers
| Metric | BIOCON.BO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 149.10 | 29.63 | Worse (Expensive) |
| ROE | 1.35% | 223.00% | Weak |
| Net Margin | 2.28% | -38669.00% (disorted) | Weak |
| Debt/Equity | 0.45 | 0.82 | Strong (Low Leverage) |
| Current Ratio | 1.22 | 4.30 | Neutral |
| ROA | 0.61% | -379.00% (disorted) | Weak |
BIOCON.BO outperforms its industry in 1 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Biocon Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation